NO963551D0 - Terapeutisk middel for behandling av lipidmetabolismeforstyrrelser - Google Patents
Terapeutisk middel for behandling av lipidmetabolismeforstyrrelserInfo
- Publication number
- NO963551D0 NO963551D0 NO963551A NO963551A NO963551D0 NO 963551 D0 NO963551 D0 NO 963551D0 NO 963551 A NO963551 A NO 963551A NO 963551 A NO963551 A NO 963551A NO 963551 D0 NO963551 D0 NO 963551D0
- Authority
- NO
- Norway
- Prior art keywords
- therapeutic agent
- lipid metabolism
- disorder
- treatment
- present
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 208000035762 Disorder of lipid metabolism Diseases 0.000 abstract 3
- 206010021024 Hypolipidaemia Diseases 0.000 abstract 2
- 208000037157 Azotemia Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 230000001919 adrenal effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000009928 nephrosis Diseases 0.000 abstract 1
- 231100001027 nephrosis Toxicity 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 230000006016 thyroid dysfunction Effects 0.000 abstract 1
- 208000009852 uremia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6337884A JPH08176007A (ja) | 1994-12-27 | 1994-12-27 | 脂質代謝異常治療剤 |
| PCT/JP1995/002707 WO1996020004A1 (en) | 1994-12-27 | 1995-12-27 | Therapeutic agent for disorder of lipid metabolism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963551D0 true NO963551D0 (no) | 1996-08-26 |
| NO963551L NO963551L (no) | 1996-10-25 |
| NO318099B1 NO318099B1 (no) | 2005-01-31 |
Family
ID=18312906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963551A NO318099B1 (no) | 1994-12-27 | 1996-08-26 | Anvendelse av Tumorcytotoksisk Faktor-II for fremstilling av et terapeutisk middel til behandling av hyperkolesterolemi og til okning av aktiviteten til lechitinkolesterolacyltransferase |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0754051B1 (no) |
| JP (1) | JPH08176007A (no) |
| KR (1) | KR100395695B1 (no) |
| AT (1) | ATE247975T1 (no) |
| AU (1) | AU710513B2 (no) |
| CA (1) | CA2184248A1 (no) |
| DE (1) | DE69531608T2 (no) |
| DK (1) | DK0754051T3 (no) |
| ES (1) | ES2201128T3 (no) |
| FI (1) | FI115826B (no) |
| HU (1) | HU220139B (no) |
| NO (1) | NO318099B1 (no) |
| NZ (1) | NZ298141A (no) |
| TW (1) | TW480173B (no) |
| WO (1) | WO1996020004A1 (no) |
| ZA (1) | ZA9510981B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| KR100568664B1 (ko) * | 1997-03-14 | 2006-06-13 | 다이이치세이야꾸 가부시끼가이샤 | 악액질 예방 및/또는 치료제 |
| US20020041863A1 (en) | 1997-03-14 | 2002-04-11 | Masamichi Kojiro | Preventive and/or therapeutic agent for cachexia |
| EP0973914B1 (en) | 1997-04-11 | 2006-12-13 | Takeda Pharmaceutical Company Limited | Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use |
| JPH1129493A (ja) * | 1997-07-14 | 1999-02-02 | Snow Brand Milk Prod Co Ltd | 放射線障害予防及び／又は治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| ATE345809T1 (de) * | 1992-07-16 | 2006-12-15 | Daiichi Seiyaku Co | Arzneimittelzusammensetzung enthaltend tcf-ii |
-
1994
- 1994-12-27 NZ NZ298141A patent/NZ298141A/xx not_active IP Right Cessation
- 1994-12-27 JP JP6337884A patent/JPH08176007A/ja not_active Withdrawn
-
1995
- 1995-12-16 TW TW084113453A patent/TW480173B/zh not_active IP Right Cessation
- 1995-12-27 EP EP95942270A patent/EP0754051B1/en not_active Expired - Lifetime
- 1995-12-27 ZA ZA9510981A patent/ZA9510981B/xx unknown
- 1995-12-27 KR KR1019960704608A patent/KR100395695B1/ko not_active IP Right Cessation
- 1995-12-27 WO PCT/JP1995/002707 patent/WO1996020004A1/en active IP Right Grant
- 1995-12-27 HU HU9602341A patent/HU220139B/hu not_active IP Right Cessation
- 1995-12-27 DK DK95942270T patent/DK0754051T3/da active
- 1995-12-27 AU AU43550/96A patent/AU710513B2/en not_active Ceased
- 1995-12-27 CA CA002184248A patent/CA2184248A1/en not_active Abandoned
- 1995-12-27 DE DE69531608T patent/DE69531608T2/de not_active Expired - Fee Related
- 1995-12-27 ES ES95942270T patent/ES2201128T3/es not_active Expired - Lifetime
- 1995-12-27 AT AT95942270T patent/ATE247975T1/de not_active IP Right Cessation
-
1996
- 1996-08-26 FI FI963312A patent/FI115826B/fi active IP Right Grant
- 1996-08-26 NO NO19963551A patent/NO318099B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE247975T1 (de) | 2003-09-15 |
| DE69531608D1 (de) | 2003-10-02 |
| JPH08176007A (ja) | 1996-07-09 |
| EP0754051A1 (en) | 1997-01-22 |
| HUT76085A (en) | 1997-06-30 |
| EP0754051B1 (en) | 2003-08-27 |
| ES2201128T3 (es) | 2004-03-16 |
| CA2184248A1 (en) | 1996-07-04 |
| NO963551L (no) | 1996-10-25 |
| AU710513B2 (en) | 1999-09-23 |
| KR100395695B1 (ko) | 2004-02-14 |
| FI963312A (fi) | 1996-08-26 |
| TW480173B (en) | 2002-03-21 |
| DK0754051T3 (da) | 2003-09-29 |
| FI963312A0 (fi) | 1996-08-26 |
| NO318099B1 (no) | 2005-01-31 |
| FI115826B (fi) | 2005-07-29 |
| KR970701058A (ko) | 1997-03-17 |
| ZA9510981B (en) | 1996-07-17 |
| NZ298141A (en) | 2000-12-22 |
| DE69531608T2 (de) | 2004-02-19 |
| HU9602341D0 (en) | 1996-10-28 |
| WO1996020004A1 (en) | 1996-07-04 |
| AU4355096A (en) | 1996-07-19 |
| HU220139B (hu) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0738152A4 (en) | USE OF 2-HYDROXY-5-PHENYLAZOBOIC ACID DERIVATIVES AS ACTIVE SUBSTANCES FOR CHEMOPREVENTION AND CHEMOTHERAPY OF COLON CANCER | |
| BE1002710A5 (fr) | Preparation au diclofenac sodique a effet prolonge. | |
| BR0114526A (pt) | Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares | |
| ES2053198T3 (es) | Sistema de suministro de un farmaco de glucano y adyuvante. | |
| AU6171796A (en) | Prodrugs of pharmaceuticals with improved bioavailability | |
| IL160643A0 (en) | Combination dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor, and aspirin | |
| TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| DE69827777D1 (de) | Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie | |
| WO2001017517A3 (en) | Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer | |
| ATE228361T1 (de) | Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen | |
| CA2170255A1 (en) | Pharmaceutical Composition for Immunoenhancement Therapy | |
| DK0696456T3 (da) | Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme | |
| HUP0003982A3 (en) | The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function | |
| NO963551L (no) | Terapeutisk middel for behandling av lipidmetabolismeforstyrrelser | |
| ATE293451T1 (de) | Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin | |
| PT1007055E (pt) | Utilizacao de amifostina | |
| DK1035859T3 (da) | Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler | |
| ZA968990B (en) | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases. | |
| Sen et al. | Cystathionine-β-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells | |
| ES2161750T3 (es) | Uso de 17alfa-dihidroequilenina para disminuir el nivel de colesterol. | |
| DE69841573D1 (de) | Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose | |
| IT1293067B1 (it) | Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico | |
| WO2004080488A3 (de) | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase | |
| EP1594513A4 (en) | CARBOHYDRATE CONJUGATES FOR PREVENTING THE ABUSE OF CONTROLLED SUBSTANCES | |
| BR0008677A (pt) | Composto de tiazolindolinona, composição farmacêutica, e, métodos papa preparar um composto de tiazolindolinona, e de prevenção/reduçao da severidade dos efeitos colaterais de citotoxicidade epitelial da quimioterapia e/ou terapia de radiação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |